---
title: "GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 1.637 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238494465.md"
datetime: "2025-05-01T21:00:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238494465.md)
  - [en](https://longbridge.com/en/news/238494465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238494465.md)
---

# GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 1.637 M

Revenue: As of FY2025 Q1, the actual value is USD 1.637 M.

EPS: As of FY2025 Q1, the actual value is USD -0.45.

### Net Loss

Net loss for the three months ended March 31, 2025, was $5.4 million, compared to $5.9 million for the same period in 2024.

### Revenue

For the three months ended March 31, 2025, GeoVax reported $1.6 million in government contract revenues associated with the BARDA/RRPV Project NextGen award, whereas no revenues were reported during the comparable 2024 period.

### Research and Development Expenses

Research and development expenses were $5.4 million for the three months ended March 31, 2025, compared to $4.4 million for the same period in 2024, primarily due to costs associated with the BARDA/RRPV Project NextGen award and the Gedeptin and GEO-MVA programs.

### General and Administrative Expenses

General and administrative expenses were $1.7 million for the three months ended March 31, 2025, compared to $1.5 million for the same period in 2024, with the increase primarily due to higher investor relations consulting costs and stock-based compensation expense.

### Cash Position

GeoVax reported cash balances of $7.4 million at March 31, 2025, compared to $5.5 million at December 31, 2024.

### Outlook / Guidance

GeoVax anticipates key data readouts for its GEO-CM04S1 COVID-19 vaccine program in the first half of 2025, with clinical trials for GEO-MVA expected to initiate in the second half of 2025. The company is advancing its Gedeptin technology into Phase 2 trials for head and neck cancer, reflecting a strategic focus on innovative immunotherapies and vaccines.

### Related Stocks

- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)

## Related News & Research

- [Goldman Sachs set to be named lead left underwriter for SpaceX IPO, source says](https://longbridge.com/en/news/286975906.md)
- [SanDisk stock slips: why this analyst still sees a 50% upside](https://longbridge.com/en/news/286938149.md)
- [Market Chatter: Intel Urges PC Makers to Adopt Advanced CPUs Amid Supply Crunch](https://longbridge.com/en/news/286955059.md)
- [EXCLUSIVE: Google's AI Monetization Strategy May Be Leaving Rivals Behind, Says Direxion](https://longbridge.com/en/news/286919559.md)
- [Here's why Astera Labs' stock just staged a big gain](https://longbridge.com/en/news/286969770.md)